OpenEvidence, a tool that doctors and nurses have likened to ChatGPT for medicine, plans to announce a 200 million dollar raise at a 6 billion dollar valuation according to The New York Times. The fresh funds come just three months after the startup raised a 210 million dollar round at a 3.5 billion dollar valuation. This rapid increase is a testament to the intense investor interest in industry-specific AI applications.
Trained on medical journals from JAMA and the New England Journal of Medicine, the OpenEvidence platform helps users quickly get answers from existing medical knowledge to help treat patients. Verified medical professionals can access OpenEvidence’s tool for free, as the platform is supported by advertising.
OpenEvidence has grown quickly since its founding in 2022. Its number of clinical consultations per month has nearly doubled to 15 million since July, as reported by the Times. This new funding round was led by Google Ventures, with participation from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft. TechCrunch has reached out to OpenEvidence for comment.